Experienced in Peripheral T-Cell Lymphoma

Dr. Akil A. Merchant

Hematology Oncology | Hematology | Oncology
Cedars-Sinai Medical Center
8700 Beverly Blvd, 
West Hollywood, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Peripheral T-Cell Lymphoma
Cedars-Sinai Medical Center
8700 Beverly Blvd, 
West Hollywood, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Akil Merchant is a Hematologist Oncology specialist and a Hematologist in West Hollywood, California. Dr. Merchant is rated as an Experienced provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 64 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Peripheral T-Cell Lymphoma.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MD
Hospital Affiliations
Cedars-Sinai Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

CEDARS-SINAI MEDICAL CENTER
8700 Beverly Blvd, West Hollywood, CA 90048

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Protocol for Immunology Specimen Collection From Cancer Patients, Patients With Hematologic Diagnoses, and Healthy Normal Controls
Protocol for Immunology Specimen Collection From Cancer Patients, Patients With Hematologic Diagnoses, and Healthy Normal Controls
Enrollment Status: Recruiting
Publish Date: July 11, 2025
Intervention Type: Other, Procedure
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 2
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Blinatumomab, Dasatinib, Mercaptopurine, Methotrexate, Methotrexate Sodium, Prednisone, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas
A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas
Enrollment Status: Suspended
Publish Date: September 10, 2025
Intervention Type: Drug
Study Drugs: Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Etoposide, Duvelisib, Oral Azacitidine
Study Phase: Phase 2
IIT2021-11-PAQUETTE-OmitMMF: Fludarabine and Total Body Irradiation 800 cGy or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil
IIT2021-11-PAQUETTE-OmitMMF: Fludarabine and Total Body Irradiation 800 cGy or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2025
Intervention Type: Other
Study Phase: Phase 2
IIT2017-05-MERIN-BLINHMCT: Blinatumomab Plus HLA-Mismatched Cellular Therapy (HMCT) for Relapsed/Refractory CD19+ ALL
IIT2017-05-MERIN-BLINHMCT: Blinatumomab Plus HLA-Mismatched Cellular Therapy (HMCT) for Relapsed/Refractory CD19+ ALL
Enrollment Status: Completed
Publish Date: February 05, 2025
Intervention Type: Drug, Other
Study Drug: Blinatumomab
Study Phase: Phase 1
A Phase I Dose Escalation Study With Expansion to Evaluate the Safety of SEPHB4-HSA in Combination With Cytarabine or Liposomal Vincristine in Patients With Relapsed or Refractory Acute Leukemia
A Phase I Dose Escalation Study With Expansion to Evaluate the Safety of SEPHB4-HSA in Combination With Cytarabine or Liposomal Vincristine in Patients With Relapsed or Refractory Acute Leukemia
Enrollment Status: Terminated
Publish Date: November 30, 2021
Intervention Type: Other, Drug, Biological
Study Drugs: Cytarabine, Vincristine, EphB4-HAS Fusion Protein
Study Phase: Phase 1
A Feasibility Study Assessing the Safety of Multiple Doses of Anti-SARS-CoV-2 Plasma in Mechanically Ventilated Intubated Patients With Respiratory Failure Due to COVID-19
A Feasibility Study Assessing the Safety of Multiple Doses of Anti-SARS-CoV-2 Plasma in Mechanically Ventilated Intubated Patients With Respiratory Failure Due to COVID-19
Enrollment Status: Terminated
Publish Date: November 08, 2021
Intervention Type: Biological
Study Drug: Anti-COVID-19 Plasma
Study Phase: Early Phase 1
View 7 Less Clinical Trials

64 Total Publications

Unmasking cancer's hidden nerve route with patient-derived organoids.
Unmasking cancer's hidden nerve route with patient-derived organoids.
Journal: Cell stem cell
Published: July 29, 2025
Similar Doctors
Elite in Peripheral T-Cell Lymphoma
Dr. Lauren C. Pinter-Brown
Hematology Oncology | Hematology | Oncology
Elite in Peripheral T-Cell Lymphoma
Dr. Lauren C. Pinter-Brown
Hematology Oncology | Hematology | Oncology

Uc Regents

101 The City Dr S, 
Orange, CA 
 (34.5 miles away)
714-456-7004
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lauren Pinter-Brown is a Hematologist Oncology specialist and a Hematologist in Orange, California. Dr. Pinter-Brown is rated as an Elite provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. Her top areas of expertise are T-Cell Lymphoma, Mycosis Fungoides, Peripheral T-Cell Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Transplant.

Distinguished in Peripheral T-Cell Lymphoma
Dr. Steven T. Rosen
Hematology Oncology | Hematology
Distinguished in Peripheral T-Cell Lymphoma
Dr. Steven T. Rosen
Hematology Oncology | Hematology

City Of Hope Medical Foundation

209 Fair Oaks Ave, 
South Pasadena, CA 
 (13.6 miles away)
626-396-2900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Steven Rosen is a Hematologist Oncology specialist and a Hematologist in South Pasadena, California. Dr. Rosen is rated as an Elite provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. His top areas of expertise are T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Distinguished in Peripheral T-Cell Lymphoma
Dr. Niloufer E. Khan
Hematology | Hematology Oncology | Pediatrics
Distinguished in Peripheral T-Cell Lymphoma
Dr. Niloufer E. Khan
Hematology | Hematology Oncology | Pediatrics

City Of Hope Medical Foundation

1500 Duarte Rd, 
Duarte, CA 
 (23.7 miles away)
626-256-4673
Languages Spoken:
English
See accepted insurances

Niloufer Khan is a Hematologist and a Hematologist Oncology provider in Duarte, California. Dr. Khan is rated as a Distinguished provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. Her top areas of expertise are T-Cell Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Merchant's expertise for a condition
ConditionClose
      View All 8 Advanced Conditions
      View All 37 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile